261 related articles for article (PubMed ID: 31533728)
1. Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types.
Chen Z; Wen W; Bao J; Kuhs KL; Cai Q; Long J; Shu XO; Zheng W; Guo X
BMC Med Genomics; 2019 Sep; 12(1):131. PubMed ID: 31533728
[TBL] [Abstract][Full Text] [Related]
2. Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment.
Vural S; Simon R; Krushkal J
Hum Genomics; 2018 Apr; 12(1):20. PubMed ID: 29642934
[TBL] [Abstract][Full Text] [Related]
3. APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism.
Chen TW; Lee CC; Liu H; Wu CS; Pickering CR; Huang PJ; Wang J; Chang IY; Yeh YM; Chen CD; Li HP; Luo JD; Tan BC; Chan TEH; Hsueh C; Chu LJ; Chen YT; Zhang B; Yang CY; Wu CC; Hsu CW; See LC; Tang P; Yu JS; Liao WC; Chiang WF; Rodriguez H; Myers JN; Chang KP; Chang YS
Nat Commun; 2017 Sep; 8(1):465. PubMed ID: 28878238
[TBL] [Abstract][Full Text] [Related]
4. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.
Middlebrooks CD; Banday AR; Matsuda K; Udquim KI; Onabajo OO; Paquin A; Figueroa JD; Zhu B; Koutros S; Kubo M; Shuin T; Freedman ND; Kogevinas M; Malats N; Chanock SJ; Garcia-Closas M; Silverman DT; Rothman N; Prokunina-Olsson L
Nat Genet; 2016 Nov; 48(11):1330-1338. PubMed ID: 27643540
[TBL] [Abstract][Full Text] [Related]
5. Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
Wen WX; Soo JS; Kwan PY; Hong E; Khang TF; Mariapun S; Lee CS; Hasan SN; Rajadurai P; Yip CH; Mohd Taib NA; Teo SH
Breast Cancer Res; 2016 May; 18(1):56. PubMed ID: 27233495
[TBL] [Abstract][Full Text] [Related]
6. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer.
Nik-Zainal S; Wedge DC; Alexandrov LB; Petljak M; Butler AP; Bolli N; Davies HR; Knappskog S; Martin S; Papaemmanuil E; Ramakrishna M; Shlien A; Simonic I; Xue Y; Tyler-Smith C; Campbell PJ; Stratton MR
Nat Genet; 2014 May; 46(5):487-91. PubMed ID: 24728294
[TBL] [Abstract][Full Text] [Related]
7. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers.
Chan K; Roberts SA; Klimczak LJ; Sterling JF; Saini N; Malc EP; Kim J; Kwiatkowski DJ; Fargo DC; Mieczkowski PA; Getz G; Gordenin DA
Nat Genet; 2015 Sep; 47(9):1067-72. PubMed ID: 26258849
[TBL] [Abstract][Full Text] [Related]
8. Impact of functional germline variants and a deletion polymorphism in APOBEC3A and APOBEC3B on breast cancer risk and survival in a Swedish study population.
Göhler S; Da Silva Filho MI; Johansson R; Enquist-Olsson K; Henriksson R; Hemminki K; Lenner P; Försti A
J Cancer Res Clin Oncol; 2016 Jan; 142(1):273-6. PubMed ID: 26320772
[TBL] [Abstract][Full Text] [Related]
9. Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer.
Gansmo LB; Sofiyeva N; Bjørnslett M; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
Sci Rep; 2021 Dec; 11(1):23463. PubMed ID: 34873230
[TBL] [Abstract][Full Text] [Related]
10. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer.
Wang S; Jia M; He Z; Liu XS
Oncogene; 2018 Jul; 37(29):3924-3936. PubMed ID: 29695832
[TBL] [Abstract][Full Text] [Related]
11. APOBEC3A/B deletion polymorphism and cancer risk.
Gansmo LB; Romundstad P; Hveem K; Vatten L; Nik-Zainal S; Lønning PE; Knappskog S
Carcinogenesis; 2018 Feb; 39(2):118-124. PubMed ID: 29140415
[TBL] [Abstract][Full Text] [Related]
12. APOBEC3A is a prominent cytidine deaminase in breast cancer.
Cortez LM; Brown AL; Dennis MA; Collins CD; Brown AJ; Mitchell D; Mertz TM; Roberts SA
PLoS Genet; 2019 Dec; 15(12):e1008545. PubMed ID: 31841499
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of APOBEC3A and 3B expression in patients with breast cancer.
Kim YS; Sun S; Yoon JS; Ko YH; Won HS; Kim JS
PLoS One; 2020; 15(3):e0230261. PubMed ID: 32176735
[TBL] [Abstract][Full Text] [Related]
14. Analysis of APOBEC3A/3B germline deletion polymorphism in breast, cervical and oral cancers from South India and its impact on miRNA regulation.
Revathidevi S; Manikandan M; Rao AK; Vinothkumar V; Arunkumar G; Rajkumar KS; Ramani R; Rajaraman R; Ajay C; Munirajan AK
Tumour Biol; 2016 Sep; 37(9):11983-11990. PubMed ID: 27155849
[TBL] [Abstract][Full Text] [Related]
15. APOBEC3A/B deletion polymorphism and endometrial cancer risk.
Sofiyeva N; Krakstad C; Halle MK; O'Mara TA; Romundstad P; Hveem K; Vatten L; Lønning PE; Gansmo LB; Knappskog S
Cancer Med; 2023 Mar; 12(6):6659-6667. PubMed ID: 36394079
[TBL] [Abstract][Full Text] [Related]
16. Germline APOBEC3B deletion influences clinicopathological parameters in luminal-A breast cancer: evidences from a southern Brazilian cohort.
Vitiello GAF; de Sousa Pereira N; Amarante MK; Banin-Hirata BK; Campos CZ; de Oliveira KB; Losi-Guembarovski R; Watanabe MAE
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1523-1532. PubMed ID: 32285256
[TBL] [Abstract][Full Text] [Related]
17. Mutational impact of APOBEC3A and APOBEC3B in a human cell line and comparisons to breast cancer.
Carpenter MA; Temiz NA; Ibrahim MA; Jarvis MC; Brown MR; Argyris PP; Brown WL; Starrett GJ; Yee D; Harris RS
PLoS Genet; 2023 Nov; 19(11):e1011043. PubMed ID: 38033156
[TBL] [Abstract][Full Text] [Related]
18. Monitoring APOBEC3A protein levels in human cancer cells.
Dananberg A; Maciejowski J
Methods Cell Biol; 2024; 182():313-327. PubMed ID: 38359985
[TBL] [Abstract][Full Text] [Related]
19. Distinct Mutagenic Activity of APOBEC3G Cytidine Deaminase Identified in Bladder Cancer.
Caswell D; Swanton C
Cancer Res; 2023 Feb; 83(4):487-488. PubMed ID: 36789568
[TBL] [Abstract][Full Text] [Related]
20. APOBEC mediated mutagenesis drives genomic heterogeneity in endometriosis.
Revathidevi S; Nakaoka H; Suda K; Fujito N; Munirajan AK; Yoshihara K; Enomoto T; Inoue I
J Hum Genet; 2022 Jun; 67(6):323-329. PubMed ID: 35017684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]